Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
EU approves Gilead's new injection for preventing HIV
03:03am, Tuesday, 26'th Aug 2025
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
03:00am, Tuesday, 26'th Aug 2025
Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
03:00am, Tuesday, 26'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the compan
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
10:55am, Friday, 22'nd Aug 2025
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Gilead unit to acquire cell therapy developer Interius for $350 million
10:21am, Thursday, 21'st Aug 2025
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
08:54am, Thursday, 21'st Aug 2025
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
10:48pm, Wednesday, 20'th Aug 2025
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
04:41pm, Wednesday, 20'th Aug 2025
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 20'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
10:25am, Monday, 18'th Aug 2025
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Our Top 10 High Growth Dividend Stocks - August 2025
08:15am, Saturday, 16'th Aug 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
10:01am, Friday, 15'th Aug 2025
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
10:55am, Friday, 08'th Aug 2025
Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
10:25am, Friday, 08'th Aug 2025
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences
05:18am, Friday, 08'th Aug 2025
A flurry of company earnings led to big stock moves early Friday.
